The Adhesion Strength of Semi-Clathrate Hydrate to Different Solid Surfaces

The adhesion between a hydrate and a pipe wall is the main cause of hydrate deposition and blockage. In this study, the adhesion strength of semi-clathrate hydrate (tetrabutylammonium bromide hydrate) to four kinds of solid surfaces (E235B carbon steel, E355CC low alloy steel, SUS304 stainless steel, and polytetrafluoroethylene) was measured. This investigation reveals that the adhesion strength of the hydrate to a solid surface is negatively correlated with the wettability of the solid surface, which suggests that hydrophobic materials effectively reduced the hydrate adhesion to the pipe wall. The surface roughness showed different effects on the adhesion of the hydrate to hydrophilic or hydrophobic surfaces. To be specific, when the surface roughness increased from 3.2 µm to 12.5 µm, the hydrate adhesion strength to the hydrophilic surface of SUS304 increased by 123.6%, whereas the hydrate adhesion strength to the hydrophobic surface of polytetrafluoroethylene only increased by 21.5%. This study shows that low wettability and low surface roughness effectively reduce the critical rate required to remove hydrate deposition, which achieves the self-removal of hydrates. At the same time, it was found that the adhesion strength of the hydrate to surfaces increases with increasing subcooling. This investigation holds significant theoretical implications for designing self-cleaning surfaces for oil and gas pipes

Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy

Tumor vaccines are emerging as one of the most promising therapeutic strategies for cancer treatment. With the advantages of low toxicity, convenient production and stable quality control, peptide vaccines have been widely used in preclinical and clinical trials involving various malignancies. However, when used alone, they still suffer from significant challenges including poor stability and immunogenicity as well as the low delivery efficiency, leading to limited therapeutic success. Herein, the STING-activating peptide nanovaccine based on human serum albumin (HSA) and biodegradable MnO2 was constructed, which can improve the stability and immunogenicity of antigenic peptides as well as facilitate their uptake by dendritic cells (DCs). Meanwhile, Mn2+ degraded from the nanovaccine can activate the STING pathway and further promote DCs maturation. In this way, the prepared nanovaccine can efficiently mediate T-cell immune responses, thereby exerting the effects of tumor prevention and therapy. Moreover, the prepared nanovaccine possesses the advantages of low cost, convenient preparation and good biocompatibility, showing great potential for practical applications